Fig. 1: Survival data.
From: Clinical trial links oncolytic immunoactivation to survival in glioblastoma
a, Kaplan–Meier survival analysis of 41 patients with rHGG (42 interventions) after treatment with CAN-3110 (day 0). The shaded area shows the 95% CIs; the Kaplan–Meier estimate of survival probability is shown. Data maturity, October 2022. Median survival time (MST), 11.6 months (95% CI = 7.8–14.9 months). b, Kaplan–Meier survival analysis of patients with IDHWT rGBM (n = 32 patients, 33 interventions), IDHmutrAA (grades 3 and 4; n = 4 patients) and IDHmut rAO (grade 3; n = 5 patients). MST, 10.9 months (IDHWTrGBM; 95% CI = 6.9–14.4 months), 5.4 months (IDHmutrAA; 95% CI = 2.6–∞ months) and 39.9 months (IDHmut rAO; 95% CI = 39.9–∞ months). Hazard ratio (HR): IDHmutrAO, 0.07 (95% CI = 0.01–0.49, P = 0.0079, two-sided Cox proportional-hazard test); IDHmutrAA, 1.09 (95% CI = 0.38–3.16, P = 0.87, two-sided Cox proportional-hazard test). c, Kaplan–Meier survival analysis of 31 patients with IDHWT rGBM (32 interventions) by negative (n = 9) or positive (n = 22 patients, 23 interventions) HSV1 serological status after treatment with CAN-3110. MST, HSV1 positive, 14.2 months (95% CI = 9.5–15.7 months); and HSV1 negative, 7.8 months (95% CI = 3.0–∞ months). P = 0.007 (two-sided likelihood ratio test). d, Kaplan–Meier survival analysis of 31 patients with IDHWT rGBM (32 interventions) by negative (n = 24 patients, 25 interventions) or positive (n = 7) HSV2 serological status before treatment with CAN-3110. MST, HSV2 positive, 6.9 months (95% CI = 2.2–∞ months); and HSV2 negative, 11.8 months (95% CI = 8.3–14.5 months). P = 0.9 (two-sided likelihood ratio test). e, Cox proportional-hazard ratio multivariate analyses for independent predictors of survival in patients with IDHWT rGBM after treatment with CAN-3110. The error bars and values in parentheses show the 95% CIs. P values calculated using two-sided Cox proportional-hazard tests are shown on the right for each covariate. The unit of tumour volume is increments of 10 cm3. Partial MGMT promoter methylation was treated as unmethylated. For patients who were administered dexamethasone within the 30 days before or after CAN-3110 treatment, the median dose was 4 mg per day, and the median number of treated days during this time was 14.5 days. KPS, Karnofsky performance score. For c–e, participant 045 was excluded due to non-GBM mortality. PFU, plaque-forming units.
